A Comparison of 6-, 12-, and 24-Monthly Dosing with Ivermectin for Treatment of Onchocerciasis

This study was designed to examine the optimal dose and interval of administration of ivermectin, the now-accepted drug of choice for onchocerciasis. Two hundred Liberians with Onchocerca volvulus infection received 100, 150,or 200 ltg/kg ivermectin or placebo and were followed for 36 months. The re...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 163; no. 2; pp. 376 - 380
Main Authors Greene, Bruce M., Dukuly, Zwannah D., Muñoz, Beatriz, White, Albert T., Pacque, Michel, Taylor, Hugh R.
Format Journal Article
LanguageEnglish
Published Chicago, IL The University Chicago Press 01.02.1991
University of Chicago Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This study was designed to examine the optimal dose and interval of administration of ivermectin, the now-accepted drug of choice for onchocerciasis. Two hundred Liberians with Onchocerca volvulus infection received 100, 150,or 200 ltg/kg ivermectin or placebo and were followed for 36 months. The reaction after the second dose of ivermectin was significantly less than after the initial dose, although it was still significant in the 200-µg/kg group. The skin microfilaria counts in the group treated 6-monthly with 150 ltg/kg was significantly less than in the group treated yearly (12 and 24 months after initial therapy). Prevalence of microfilariae in the anterior chamber and punctate corneal opacities decreased progressively in all groups over 3 years. There appears to be a slight advantage, in terms of antiparasitic effect over the first 2 years, of therapy given 6-monthly compared with yearly.
Bibliography:Reprints or correspondence: Dr. Bruce M. Greene, Division of Geographic Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.
istex:09C826C7572F54E0B89FD0F8DD6A85FF60707048
ark:/67375/HXZ-Z153CW95-L
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/163.2.376